No generic version of Yupelri is currently available [1].
What is Yupelri and What is it Used For?
Yupelri (revefenacin) is a once-daily, long-acting muscarinic antagonist (LAMA) used for the maintenance treatment of adults with chronic obstructive pulmonary disease (COPD) [2, 3]. It works by relaxing the muscles in the airways, making breathing easier [2].
When Does Yupelri's Patent Expire?
The patent protection for Yupelri is complex, involving multiple patents. DrugPatentWatch.com data indicates that the earliest significant patent expiration related to Yupelri is in 2032 [4]. However, other patents may extend further, potentially influencing the availability of generics.
Who Makes Yupelri?
Yupelri was developed by Mylan N.V. and Theravance Biopharma, and is marketed by Mylan, now part of Viatris [5, 6].
What are the Risks Associated with Yupelri?
Potential risks and side effects of Yupelri include acute angle closure glaucoma and urinary retention [2]. Patients with a history of these conditions should use Yupelri with caution [2].
What are the Next Steps for Generic Yupelri?
The availability of generic versions of Yupelri will depend on the expiration of its patents and any successful patent challenges. Companies interested in developing generics would typically file an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) once patent exclusivity has ended or is expected to end [7].
---
Sources
1. https://www.drugpatentwatch.com/
2. https://www. Yupelri.com/
3. https://www.ncbi.nlm.nih.gov/pubmed/30623507
4. https://www.drugpatentwatch.com/p/yupelri-revefenacin-patents
5. https://www.fiercebiotech.com/biotech/theravance-mylan-ink-us-yen-deal-chronic-copd-drug- Yupelri
6. https://www.viatris.com/en/newsroom/press-releases/2020/11/mylan-and-upjohn-complete-combination-to-form-viatris
7. https://www.fda.gov/drugs/abbreviated-new-drug-applications-andas/andas